Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) to Post FY2028 Earnings of $11.61 Per Share, Brookline Capital Management Forecasts

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) – Stock analysts at Brookline Capital Management issued their FY2028 earnings per share estimates for Syros Pharmaceuticals in a report released on Wednesday, March 27th. Brookline Capital Management analyst L. Cann forecasts that the company will post earnings per share of $11.61 for the year. The consensus estimate for Syros Pharmaceuticals’ current full-year earnings is ($4.73) per share.

Separately, StockNews.com raised Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday.

Syros Pharmaceuticals Trading Down 8.4 %

Shares of SYRS stock opened at $5.35 on Thursday. The company has a market cap of $112.72 million, a P/E ratio of -1.43 and a beta of 1.79. The stock has a 50 day simple moving average of $6.86 and a two-hundred day simple moving average of $5.06. The company has a debt-to-equity ratio of 1.09, a quick ratio of 4.31 and a current ratio of 4.31. Syros Pharmaceuticals has a fifty-two week low of $2.09 and a fifty-two week high of $8.17.

Institutional Trading of Syros Pharmaceuticals

Hedge funds have recently bought and sold shares of the business. Clarius Group LLC bought a new stake in Syros Pharmaceuticals during the third quarter worth $74,000. Assenagon Asset Management S.A. raised its stake in shares of Syros Pharmaceuticals by 142.2% in the third quarter. Assenagon Asset Management S.A. now owns 25,130 shares of the company’s stock valued at $99,000 after buying an additional 14,754 shares during the period. CHI Advisors LLC raised its stake in shares of Syros Pharmaceuticals by 69.3% in the third quarter. CHI Advisors LLC now owns 1,299,359 shares of the company’s stock valued at $5,119,000 after buying an additional 531,914 shares during the period. Avidity Partners Management LP raised its stake in shares of Syros Pharmaceuticals by 8.0% in the third quarter. Avidity Partners Management LP now owns 1,581,142 shares of the company’s stock valued at $6,246,000 after buying an additional 117,108 shares during the period. Finally, Shay Capital LLC raised its stake in shares of Syros Pharmaceuticals by 87.3% during the 2nd quarter. Shay Capital LLC now owns 26,426 shares of the company’s stock valued at $83,000 after purchasing an additional 12,317 shares during the period. 91.47% of the stock is currently owned by institutional investors.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.